* Spark Therapeutics and Pfizer announce updated data from
first cohort in Hemophilia B phase 1/2 trial demonstrating
consistent, sustained therapeutic levels of factor ix activity
The post BRIEF-Spark Therapeutics and Pfizer announce data from first cohort in Hemophilia B Phase 1/2 trial appeared first on NASDAQ.